Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence
Reactive oxygen species (ROS) are metabolic byproducts that regulate various cellular processes. However, at high levels, ROS induce oxidative stress, which in turn can trigger cell death. Cancer cells alter the redox homeostasis to facilitate protumorigenic processes; however, this leaves them vuln...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-05-01
|
| Series: | Antioxidants |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-3921/12/6/1159 |
| _version_ | 1797596395851481088 |
|---|---|
| author | Zohra Nausheen Nizami Hanan E. Aburawi Abdelhabib Semlali Khalid Muhammad Rabah Iratni |
| author_facet | Zohra Nausheen Nizami Hanan E. Aburawi Abdelhabib Semlali Khalid Muhammad Rabah Iratni |
| author_sort | Zohra Nausheen Nizami |
| collection | DOAJ |
| description | Reactive oxygen species (ROS) are metabolic byproducts that regulate various cellular processes. However, at high levels, ROS induce oxidative stress, which in turn can trigger cell death. Cancer cells alter the redox homeostasis to facilitate protumorigenic processes; however, this leaves them vulnerable to further increases in ROS levels. This paradox has been exploited as a cancer therapeutic strategy with the use of pro-oxidative drugs. Many chemotherapeutic drugs presently in clinical use, such as cisplatin and doxorubicin, induce ROS as one of their mechanisms of action. Further, various drugs, including phytochemicals and small molecules, that are presently being investigated in preclinical and clinical studies attribute their anticancer activity to ROS induction. Consistently, this review aims to highlight selected pro-oxidative drugs whose anticancer potential has been characterized with specific focus on phytochemicals, mechanisms of ROS induction, and anticancer effects downstream of ROS induction. |
| first_indexed | 2024-03-11T02:49:50Z |
| format | Article |
| id | doaj.art-8935613d6af842d2a4754c631ead1589 |
| institution | Directory Open Access Journal |
| issn | 2076-3921 |
| language | English |
| last_indexed | 2024-03-11T02:49:50Z |
| publishDate | 2023-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antioxidants |
| spelling | doaj.art-8935613d6af842d2a4754c631ead15892023-11-18T09:02:16ZengMDPI AGAntioxidants2076-39212023-05-01126115910.3390/antiox12061159Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical EvidenceZohra Nausheen Nizami0Hanan E. Aburawi1Abdelhabib Semlali2Khalid Muhammad3Rabah Iratni4Department of Biology, College of Science, United Arab Emirates University, Al Ain PO Box 15551, United Arab EmiratesDepartment of Biology, College of Science, United Arab Emirates University, Al Ain PO Box 15551, United Arab EmiratesGroupe de Recherche en Écologie Buccale, Faculté de Médecine Dentaire-Université Laval, Quebec, QC G1V 0A6, CanadaDepartment of Biology, College of Science, United Arab Emirates University, Al Ain PO Box 15551, United Arab EmiratesDepartment of Biology, College of Science, United Arab Emirates University, Al Ain PO Box 15551, United Arab EmiratesReactive oxygen species (ROS) are metabolic byproducts that regulate various cellular processes. However, at high levels, ROS induce oxidative stress, which in turn can trigger cell death. Cancer cells alter the redox homeostasis to facilitate protumorigenic processes; however, this leaves them vulnerable to further increases in ROS levels. This paradox has been exploited as a cancer therapeutic strategy with the use of pro-oxidative drugs. Many chemotherapeutic drugs presently in clinical use, such as cisplatin and doxorubicin, induce ROS as one of their mechanisms of action. Further, various drugs, including phytochemicals and small molecules, that are presently being investigated in preclinical and clinical studies attribute their anticancer activity to ROS induction. Consistently, this review aims to highlight selected pro-oxidative drugs whose anticancer potential has been characterized with specific focus on phytochemicals, mechanisms of ROS induction, and anticancer effects downstream of ROS induction.https://www.mdpi.com/2076-3921/12/6/1159reactive oxygen speciescancer therapyphytochemicalsoxidative stress |
| spellingShingle | Zohra Nausheen Nizami Hanan E. Aburawi Abdelhabib Semlali Khalid Muhammad Rabah Iratni Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence Antioxidants reactive oxygen species cancer therapy phytochemicals oxidative stress |
| title | Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence |
| title_full | Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence |
| title_fullStr | Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence |
| title_full_unstemmed | Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence |
| title_short | Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence |
| title_sort | oxidative stress inducers in cancer therapy preclinical and clinical evidence |
| topic | reactive oxygen species cancer therapy phytochemicals oxidative stress |
| url | https://www.mdpi.com/2076-3921/12/6/1159 |
| work_keys_str_mv | AT zohranausheennizami oxidativestressinducersincancertherapypreclinicalandclinicalevidence AT hananeaburawi oxidativestressinducersincancertherapypreclinicalandclinicalevidence AT abdelhabibsemlali oxidativestressinducersincancertherapypreclinicalandclinicalevidence AT khalidmuhammad oxidativestressinducersincancertherapypreclinicalandclinicalevidence AT rabahiratni oxidativestressinducersincancertherapypreclinicalandclinicalevidence |